AAPA Members, login to view FREE Full Text for all articles. Not a member? Join today!

Institutional members access full text with Ovid®

Share this article on:

Canagliflozin: A new option for managing diabetes

Livingston, Molly PharmD; Clements, Jennifer N. PharmD, BCPS, CDE, BCACP

Journal of the American Academy of Physician Assistants: September 2014 - Volume 27 - Issue 9 - p 47–50
doi: 10.1097/01.JAA.0000453247.76333.09
What's New in Diabetes

ABSTRACT Canagliflozin is a sodium glucose cotransporter 2 inhibitor for patients with type 2 diabetes and can be given as monotherapy or in combination with other agents, including insulin. Taken orally once daily, canagliflozin can reduce weight and BP, but has been associated with genital mycotic infections.

At the time this article was written, Molly Livingston was a student in the doctor of pharmacy program at Presbyterian College School of Pharmacy in Clinton, S.C. Jennifer N. Clements is an associate professor in the Department of Pharmacy Practice at Presbyterian College School of Pharmacy.

The authors have disclosed no potential conflicts of interest, financial or otherwise.

Mark E. Archambault, DHSc, PA-C, department editor

© 2014 American Academy of Physician Assistants.
You currently do not have access to this article

To access this article:

Note: If your society membership provides full-access, you may need to login on your society website